Cord Blood Transplantation Using Myeloablative Conditioning for Pediatric Advanced Myelodysplastic Syndrome in AMeD Syndrome With a Novel ADH5 Variant

Yusuke Morishita,Motoharu Hamada,Suguru Uemura,Hiroaki Kikuchi,Hiroaki Hisakawa,Tomoko Fujikawa,Akihiro Tamura,Yusuke Okuno,Manabu Wakamatsu,Hideki Muramatsu,Yoshiyuki Takahashi,Daiichiro Hasegawa,Yoshiyuki Kosaka
DOI: https://doi.org/10.1002/pbc.31465
2024-12-01
Pediatric Blood & Cancer
Abstract:Aplastic anemia, mental retardation, and dwarfism syndrome (AMeDS) is a rare inherited bone marrow failure syndrome. Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the only possible treatment option for hematological complications in AMeDS; however, there are no reports addressing allo‐HSCT for AMeDS. A 6‐year‐old female diagnosed with AMeDS accompanying myelodysplastic syndrome with increased blast was successfully treated with cord blood transplantation followed by myeloablative conditioning (MAC). A novel ADH5 c.1101‐3C>G variant detected in this patient was demonstrated to be a null variant causing several patterns of alternative splicing in ADH5 gene. MAC might be feasible and effective in AMeDS.
oncology,pediatrics,hematology
What problem does this paper attempt to address?